26 The drug that has advanced furthest through development, in fact all the way to market, is Eli Lilly and Companys (Indianapolis, Indiana, USA) tirzepatide (LY3298176), a unimolecular dual GIP/GLP-1 RA
Drugs require specialist prescription
GLP-1RAs and cardiovascular-renal outcomes in type 2 diabetes systematic review (2021) highlights significant reductions in cardiovascular events, kidney disease progression, and mortality among GLP-1 users
For natural ingredient patches, no high-quality human trials currently validate this delivery method for weight management
Studies suggest appetite reduction may begin within a few weeks of starting GLP-1 medications, while meaningful changes in weight metrics may appear after 820 weeks, with continued improvement over 6 months or more
That side effect would soon become the headline